Overview

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

Status:
Recruiting
Trial end date:
2023-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults aged 50 years and older.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline